Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study

Background Oral and intravenous formulations of ciprofloxacin have established efficacy and safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis’ PulmoSphere™ technology has been developed to deliver high concentrations of ciprofloxacin to the lung with low...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical drug investigation 2013-06, Vol.33 (6), p.419-427
Hauptverfasser:	Stass, Heino, Nagelschmitz, Johannes, Willmann, Stefan, Delesen, Heinz, Gupta, Abhishek, Baumann, Sybille
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Inhalation Adult Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - pharmacokinetics Area Under Curve Ciprofloxacin - administration & dosage Ciprofloxacin - adverse effects Ciprofloxacin - pharmacokinetics Cross-Over Studies Dry Powder Inhalers Half-Life Humans Internal Medicine Lung - metabolism Male Medicine Medicine & Public Health Original Original Research Article Pharmacology/Toxicology Pharmacotherapy Single-Blind Method Tissue Distribution
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!